These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

589 related articles for article (PubMed ID: 26282377)

  • 1. Design considerations for nanotherapeutics in oncology.
    Stylianopoulos T; Jain RK
    Nanomedicine; 2015 Nov; 11(8):1893-907. PubMed ID: 26282377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineered nanoparticles for drug delivery in cancer therapy.
    Sun T; Zhang YS; Pang B; Hyun DC; Yang M; Xia Y
    Angew Chem Int Ed Engl; 2014 Nov; 53(46):12320-64. PubMed ID: 25294565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Targeting of Cancers with Nanotherapeutics.
    Foster C; Watson A; Kaplinsky J; Kamaly N
    Methods Mol Biol; 2017; 1530():13-37. PubMed ID: 28150194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prodrugs in combination with nanocarriers as a strategy for promoting antitumoral efficiency.
    Lin MH; Hung CF; Hsu CY; Lin ZC; Fang JY
    Future Med Chem; 2019 Aug; 11(16):2131-2150. PubMed ID: 31538520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
    Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
    Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
    Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
    Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical developments in nanotechnology for cancer therapy.
    Heidel JD; Davis ME
    Pharm Res; 2011 Feb; 28(2):187-99. PubMed ID: 20549313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotargeted agents: an emerging therapeutic strategy for breast cancer.
    Du M; Ouyang Y; Meng F; Ma Q; Liu H; Zhuang Y; Pang M; Cai T; Cai Y
    Nanomedicine (Lond); 2019 Jul; 14(13):1771-1786. PubMed ID: 31298065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
    Prabhakar U; Maeda H; Jain RK; Sevick-Muraca EM; Zamboni W; Farokhzad OC; Barry ST; Gabizon A; Grodzinski P; Blakey DC
    Cancer Res; 2013 Apr; 73(8):2412-7. PubMed ID: 23423979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Research Progress of Disulfide Bond Based Tumor Microenvironment Targeted Drug Delivery System.
    Ma W; Wang X; Zhang D; Mu X
    Int J Nanomedicine; 2024; 19():7547-7566. PubMed ID: 39071505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.
    Piktel E; Niemirowicz K; Wątek M; Wollny T; Deptuła P; Bucki R
    J Nanobiotechnology; 2016 May; 14(1):39. PubMed ID: 27229857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology.
    Bertrand N; Wu J; Xu X; Kamaly N; Farokhzad OC
    Adv Drug Deliv Rev; 2014 Feb; 66():2-25. PubMed ID: 24270007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Implications of nanotechnology for the treatment of cancer: Recent advances.
    Klochkov SG; Neganova ME; Nikolenko VN; Chen K; Somasundaram SG; Kirkland CE; Aliev G
    Semin Cancer Biol; 2021 Feb; 69():190-199. PubMed ID: 31446004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stimuli-Responsive Programmed Specific Targeting in Nanomedicine.
    Wang S; Huang P; Chen X
    ACS Nano; 2016 Mar; 10(3):2991-4. PubMed ID: 26881288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Influencing the Delivery Efficiency of Cancer Nanomedicines.
    Ullah R; Wazir J; Khan FU; Diallo MT; Ihsan AU; Mikrani R; Aquib M; Zhou X
    AAPS PharmSciTech; 2020 May; 21(4):132. PubMed ID: 32409932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes.
    Palazzolo S; Bayda S; Hadla M; Caligiuri I; Corona G; Toffoli G; Rizzolio F
    Curr Med Chem; 2018; 25(34):4224-4268. PubMed ID: 28875844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delivering nanomedicine to solid tumors.
    Jain RK; Stylianopoulos T
    Nat Rev Clin Oncol; 2010 Nov; 7(11):653-64. PubMed ID: 20838415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?
    Nakamura Y; Mochida A; Choyke PL; Kobayashi H
    Bioconjug Chem; 2016 Oct; 27(10):2225-2238. PubMed ID: 27547843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new era of pancreatic cancer treatment: Application of nanotechnology breaking through bottlenecks.
    Luo W; Zhang T
    Cancer Lett; 2024 Jul; 594():216979. PubMed ID: 38795762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating Nanomedicines: Obstacles and Advancements.
    Swierczewska M; Crist RM; McNeil SE
    Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.